Targeted Antigen Delivery to DEC-205+Dendritic Cells for Tolerogenic Vaccination
Author(s) -
Cathleen Petzold,
Sonja Schallenberg,
Joel N. H. Stern,
Karsten Kretschmer
Publication year - 2012
Publication title -
the review of diabetic studies
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 41
eISSN - 1614-0575
pISSN - 1613-6071
DOI - 10.1900/rds.2012.9.305
Subject(s) - foxp3 , immunology , antigen presenting cell , t cell , autoimmunity , immune tolerance , dendritic cell , cd40 , biology , antigen , immune system , microbiology and biotechnology , cytotoxic t cell , genetics , in vitro
Dendritic cells (DCs) and Foxp3-expressing CD4⁺ regulatory T (Treg) cells play non-redundant roles in the maintenance of peripheral tolerance to self-antigens, thereby preventing fatal autoimmunity. A common hallmark of intra- and extra-thymic Treg cell lineage commitment is the induction of Foxp3 expression as a consequence of appropriate T cell receptor engagement with MHC class II:agonist ligand. It has now become increasingly clear that agonist ligand presentation by immature DCs in the steady state induces T cell tolerance by both recessive and dominant mechanisms, rather than promoting productive T helper cell responses. In this context, the ability of steady-state DCs to promote the extrathymic conversion of initially naïve CD4⁺Foxp3⁻ T cells into Foxp3⁺ Treg cells is of particular interest as it provides novel perspectives to enhance antigen-specific Treg cell function in clinical settings of unwanted immunity, such as β-cell autoimmunity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom